Update: Improvement in Huntington’s disease patients in Skyhawk Therapeutics trial

“Skyhawk Therapeutics announces twelve-month results from Phase 1/2 clinical trial of SKY-0515 in Huntington’s disease.”

See the full article here:

https://www.hda.org.uk/news/improvement-in-huntingtons-disease-patients-in-skyhawk-therapeutics-trial/?fbclid=IwY2xjawSK0ZJleHRuA2FlbQIxMABicmlkETF2blNzVmZwUkdKNVBLaTVIc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHhgg2aNTt20l3b9AQ5wZn0niDF1zyTU4PJfEHdmlbVoOgs1eU3cBBuwLBcVo_aem_Rm5hVdb90gjJJPjY_tmQgQ